Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus.

Richard A FurieRonald F van VollenhovenKenneth KalunianSandra NavarraJuanita Romero-DiazVictoria P WerthXiaobi HuangGeorge ClarkHua CarrollAdam MeyersCristina MusselliCatherine BarbeyNathalie Franchimontnull null

Published in: The New England journal of medicine (2022)

In a phase 2 trial involving participants with SLE, litifilimab was associated with a greater reduction from baseline in the number of swollen and tender joints than placebo over a period of 24 weeks. Longer and larger trials are required to determine the safety and efficacy of litifilimab for the treatment of SLE. (Funded by Biogen; LILAC ClinicalTrials.gov number, NCT02847598.).

Keyphrases

systemic lupus erythematosus
disease activity
phase iii
clinical trial
study protocol
randomized controlled trial
phase ii
double blind
smoking cessation